All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance
During the 2021 ASCO Annual Meeting, the MDS Hub spoke with Mikkael A. Sekeres, Sylvester Comprehensive Cancer Center, Miami, US. We asked, What baseline factors affect quality of life (QoL) in MDS? How do these change with treatment?
What baseline factors affect QoL in MDS? How do these change with treatment?
Sekeres firstly defines QoL assessment in MDS, and highlights the effect of cytopenia. He also discusses the challenges of measuring changes in QoL with treatment, particularly for randomized trials. Finally, he proposes improvements to QoL assessment, focusing on wearables that measure activity.
Results from the phase II P-2001 study on pevonedistat plus azacytidine for high-risk MDS
To further explore the clinical efficacy and safety of pevo in patients with high-risk MDS, CMML, or low-blast AML, Mikkael Sekeres and colleagues designed the...
Practice-changing abstracts in myelodysplastic syndromes
World-leading experts in MDS shared the top abstracts from ASH 2020 that they believed could have the greatest impact on clinical practice.
Subscribe to get the best content related to MDS delivered to your inbox